Compare Moderna, Inc. (MRNA) vs Warner Music Group Corp (WMG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Warner Music Group Corp — how do they compare? Moderna, Inc. trades at $59.66 (market cap $23.60B), while Warner Music Group Corp trades at $28.2 (market cap $14.64B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Warner Music Group Corp pays a 2.71% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | WMG | |
|---|---|---|
Market Cap | $23.60B | $14.64B |
Sector | Health | Media |
52-Week High | $81.80 | $34.72 |
52-Week Low | $22.36 | $23.65 |
Enterprise Value | $19.70B | $18.84B |
Dividend Yield | — | 2.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $59.66, down 3.49% in the last session amid broader biotech volatility. The stock shows a mixed technical picture with bullish overall signals but bearish moving averages. Fundamentally, revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B. Recent positive developments include an EU RSV vaccine contract and progress in cancer immunotherapy trials, with Q2 2026 earnings due July 31.
Outlook remains speculative as Moderna transitions beyond COVID-19 vaccines. Opportunities lie in its expanding pipeline in oncology and flu vaccines, but risks include sustained losses, competitive pressure, and execution hurdles. Analyst consensus is cautious with a $49 price target below current levels, reflecting uncertainty over profitability timeline.
Warner Music Group (WMG) trades at $27.945, down 1.36% on the day, amid a bearish technical signal. The stock shows mixed earnings performance, with a Q1 2026 beat but recent quarterly misses. Revenue growth is steady, reaching $6.71B in 2025, though net income margin has compressed to 5.44%. Recent strategic moves include a licensing renewal with NetEase Cloud Music and the acquisition of AI startup Sureel AI, positioning the company for growth in digital and AI-driven music markets.
WMG presents a compelling long-term opportunity with analyst consensus pointing to significant upside (target $41.00), supported by 66.66% buy ratings. However, risks include competitive pressures in streaming, margin volatility, and execution challenges in integrating AI technologies. The stock's current valuation multiples (P/E 33.4) suggest premium pricing relative to earnings, requiring sustained growth to justify investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Warner Music Group Corp
Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →
